HOUSE GOVERNMENT REFORM COMMITTEE COULD TAKE MORE INTEREST IN FDA UNDER REPS. BURTON, WAXMAN; REP. HALL IS RANKING COMMERCE/HEALTH SUBCMTE. DEMOCRAT
This article was originally published in The Gray Sheet
The new chairman of the House Government Reform & Oversight Committee, Indiana Republican Dan Burton, is a co-sponsor of agency reform legislation and has paid attention to agency policy issues such as the MedGuide drug regulation.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.